I see few sell side model updates for GILD for Kite Pharma purchase. The revenue predictions are running $1.5 to $5.5 but after 3 years, peaking around 2022, and the range based on the assumption of various % of the success of the pipeline.
So I am trying to understand what is the upside for Gilead in this purchase.
“…it wants to become a major player in oncology, and it’s willing to do that not by buying an individual drug, but buying a platform that will allow it to develop drug after drug after drug for increasingly more indications, and that platform is CAR-T.”